Short answer
DiaMedica Therapeutics Inc. (DMAC) filed its Q2 2026 10-Q quarterly report on Aug 10, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$10M
- −31.7% YoY · −1.0% QoQ
- EPS (diluted)
- −$0.19
- −5.6% YoY · +0.0% QoQ
Source: XBRL data from the DiaMedica Therapeutics Inc. (DMAC) Q2 2026 10-Q on SEC EDGAR. USD.
DiaMedica Therapeutics Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0; no product sales, with no commercial approval
- Net loss $8.9M for the quarter, versus no quarterly net-loss figure disclosed for 2025
- R&D expense $8.2M vs $5.8M YoY; G&A expense $2.3M vs $2.2M
- Cash, equivalents and securities $43.5M vs $59.9M at December 31, 2025; operating cash use $17.2M six months
- ReMEDy2 enrollment 85% toward interim analysis; slower activations and enrollment, with analysis estimated in first quarter 2027
Risk Factors
- No material risk-factor changes from the December 31, 2025 Form 10-K
- Carried-forward risks remain applicable to DiaMedica’s business, financial condition, and results
- Unknown or currently immaterial risks could impair future operating results
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other DiaMedica Therapeutics Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.